Avirmax CMC Inc. (ACI) is a California CDMO that operates as a spinoff entity of the San Francisco Bay Area–based viral vector company Avirmax Biopharma. ACI provides high-quality non-GMP and GMP rAAV and pDNA production through their robust manufacturing platform. The ACI team has exemplary expertise in AAV vector design, engineering, process development, analytical testing, and manufacturing. Through their new 20,000-sq.-ft. facility that opened in 2023, they can deliver high-yield and high-quality vectors quickly, efficiently, and cost effectively.